Volume 5, Issue 5
Drug Evaluationp. 605
Dirucotide (MBP8298) for the treatment of multiple sclerosis
Author(s): Clyde Markowitz
Appendicesp. 726
Author guidelines: Volume 5 Issue 5
Appendicesp. 725
Acknowledgment: Volume 5 Issue 5
Appendicesp. 721
Indices: Volume 5 Issue 5
Appendicesp. 719
Glossary: Volume 5 Issue 5
Perspectivep. 707
HIV drug policies and South markets: settling controversies
Author(s): Daniele Dionisio, Claudio Fabbri and Daniela Messeri
Research Articlep. 697
Study of the extraction, purification and antidiabetic potential of ursolic acid from Cornus officinalis Sieb. et Zucc.
Author(s): Dawei Gao, Na Li, Qingwang Li, Jian Li, Zengsheng Han, Yusheng Fan and Zhiwei Liu
Review Articlep. 631
Endoplasmic reticulum stress response as a potential therapeutic target in multiple sclerosis
Author(s): Meghann Teague Getts, Daniel R Getts, Adam P Kohm and Stephen D Miller
Review Articlep. 623
Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient
Author(s): Manuel Comabella
Review Articlep. 613
Novel designs for clinical trials in multiple sclerosis: another excursion to Sirenum scopuli?
Author(s): Stacey S Cofield and Gary R Cutter
Forewordp. 585
Multiple sclerosis therapeutics: opportunities, strategies and challenges
Author(s): Richard A Rudick
Drug Evaluationp. 667
Desmopressin for the treatment of adult nocturia
Author(s): Hashim Hashim and Paul Abrams
Priority Paper Evaluationp. 663
Efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, in rheumatoid arthritis
Author(s): Yoshiyuki Ohsugi
Appendicesp. 659
Bulletin Board: Volume 5 Issue 5
Research Highlightsp. 601
Highlights from the latest articles in multiple sclerosis
Interviewp. 597
Dr Leslie Weiner speaks to Charlotte Barker, Commissioning Editor
Author(s): Leslie P Weiner
News and Viewsp. 593
Multiple sclerosis therapeutics
Editorialp. 589
What are new therapies teaching us about the immunology of multiple sclerosis?
Author(s): Michael K Racke and Amy E Lovett-Racke
